Vertex Q3 product revenue $2.48B (+6% YoY); raises FY2023 guidance to ~$9.85B

VERTEX PHARMACEUTICALS INC / MA

2023-Q3 EPS reported $10.18 revenue$7,351,500,000

Product revenue $2.48B (+6% YoY); U.S. $1.55B (+7%), ex-U.S. $929M (+6%).
FY2023 product revenue guidance raised to ~$9.85B (from $9.7-9.8B); opex guidance unchanged.
Exa-cel PDUFA for SCD Dec 8, 2023; BLA Priority Review; EU/UK reviews ongoing.
Phase 3 data for vanzacaftor triple and VX-548 acute pain expected early 2024; Phase 2 neuropathic pain data late 2023.
Cash and marketable securities $13.6B at Sep 30, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA updated its full year 2023 guidance (raised).

Period: full year 2023
Guidance: raised
Result: guidance update

Exact text from the filing

Vertex today raised its full year 2023 CF product revenue guidance to approximately $9.85 billion.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

VERTEX PHARMACEUTICALS INC / MA reported third quarter ended September 30, 2023 results: revenue $2.48 billion. Guidance raised.

Period: third quarter ended September 30, 2023
Revenue: $2.48 billion
Guidance: raised
Result: reported results

Exact text from the filing

as shall be expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Vertex Reports Third Quarter 2023 Financial Results — Product revenue of $2.48 billion, a 6% increase compared to Q3 2022 — — Company raises full year 2023 product revenue guidance to approximately $9.85 billion — — U.S. FDA Advisory Committee meeting for exa-cel

View on SEC.gov

2 earnings releases filed in the last 30 days. Browse all earnings releases →

VERTEX PHARMACEUTICALS INC / MA filing history →

Source: SEC EDGAR

accession 0000875320-23-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.